BIND Therapeutics' Presentations at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics

BIND Therapeutics, Inc.

, a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that four abstracts have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, November 5-9, 2015. The abstracts were published today on the AACR website at www.AACR.org. "These posters highlight compelling data across multiple payloads and therapeutic pathways that reinforce what we believe is a powerful platform with the potential to create best-in-class therapeutics," said Andrew Hirsch, president and chief executive officer at BIND. "These data add to a growing body of evidence that further validate the ability of our Accurins to control the biodistribution of therapeutic payloads to target diseased cells while limiting exposure to healthy tissues and minimizing on-target but off-tissue toxicities. We are committed to creating innovative medicines, both through internal discovery and collaborations with leading biopharmaceutical companies, that fully leverage the benefits of our proprietary nanomedicine platform." The posters will include preclinical and clinical pharmacokinetic data from BIND's clinical stage Accurin compound, BIND-014, data from BIND's preclinical stage Accurin, BIND-510, and new data from a previously unannounced feasibility study with Merck, demonstrating the potential value of an Accurin formulation of Merck's proprietary AKT inhibitor, MK-2206. Poster presentations at AACR include the following: BIND-014 1. Poster title: Cardiovascular safety profile of BIND-014 (docetaxel nanoparticles for injectable suspension) evaluated in phase 1 and 2 studies (Abstract/poster board #A161) Date/time: November 6, 2015; 12:15 – 3:15 pm ET Poster session category: Therapeutic Agents: Other Location: Poster Session A; Exhibit hall C-D 2. Poster title: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study (Abstract/poster board #B144) Date/time: November 7, 2015; 12:30 – 3:30 pm ET Poster session category: Pharmacokinetics and Pharmacodynamics Location: Poster Session B; Exhibit hall C-D BIND-510 1. Poster Title: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate (Abstract/poster board #C184) Date/time: November 8, 2015; 12:30 – 3:15 pm ET Poster session category: Therapeutic Agents: Other Location: Poster Session C; Exhibit Hall C-D MK-2206 Accurin 1. Poster Title: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206 (Abstract/poster board #C197) Collaborator: Merck Date/time: November 8, 2015; 12:30 – 3:30 pm ET Poster session category: Therapeutic Agents: Small Molecule Kinase Inhibitors Location: Poster Session C About Accurins™ Accurins are BIND's targeted and programmable therapeutics, which are designed, utilizing BIND's medicinal nanoengineering platform, with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression, achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form, and have pharmacokinetics and tolerability differentiated from their therapeutic payloads.